Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 19 November 2013 | By Alexander Gaffney, RAC,
EU regulators and health technology assessment (HTA) experts have announced their plans to collaborate more closely over the next three years, saying existing efforts need to be expanded to include earlier interactions and new approaches.
The plan, announced on 19 November 2013, involves the European Medicines Agency (EMA) and EUnetHTA, an EU-wide group of HTA bodies. HTA involves the assessment of medicines for their real-world impact and cost-effectiveness, and is hugely important in countries where public systems ultimately choose whether or not to reimburse for the use of a drug.
The UK's HTA body, the National Institute for Health and Care Excellence (NICE), for example, operates as a de facto second gatekeeper to market access. Even if a drug has obtained EMA's blessing to be marketed across the EU, without HTA bodies having sufficient evidence to show the costs of the treatment are outweighed by its benefits, a drug might not reach many patients.
As a result, in recent years regulators and HTA bodies have been working together to try to harmonize their requirements for evidence in the hopes that evidence used to support regulatory approval might also be used to support approval from HTA bodies as well.
The trend has also coincided with efforts to expand EU-wide HTA capacity. In June 2013, the European Commission implemented a new set of rules to establish an EU HTA network meant to "support and facilitate cooperation and the exchange of information among Member States working within a voluntary network connecting national authorities responsible for HTA."
The network, known as the "HTA Network," is voluntary for Member States to either join or leave, but is intended to avoid the duplication of assessments and the resources it takes to generate them. The assessments themselves are meant to capture the total value of a product within the context of a patient and their place in society, and come up with a reimbursement value that would be reasonable for a government.
Since 2010, EMA and EUnetHTA have been collaborating in an attempt to better harmonize regulatory and payor data requirements. According to both, "The project has resulted in a series of improvements to the European public assessment report (EPAR) template," which is used to communicate the benefits and risks of a medicine.
While the outcomes from that initial collaboration are still being analyzed, the groups today said they plan to expand those efforts into four additional areas over the next three years:
The plan will be updated on an annual basis, regulators said.
EMA/EUnetHTA Statement
Tags: EU
Regulatory Focus newsletters
All the biggest regulatory news and happenings.